Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis continues to grow with further core margin expansion and achieves important innovation milestones
Ad hoc announcement pursuant to Art. 53 LR Full year Net sales grew +4% (cc1, -2% USD) with core operating income growing +8% (cc, 0% USD) IM sales grew +4% (cc, -2% USD) and core operating
Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis delivers mid single digit sales growth, margin expansion and advancement of robust pipeline in 2021
Where are the rock stars of climatology? scienceblogs.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from scienceblogs.com Daily Mail and Mail on Sunday newspapers.
13 1Refers to continuing operations as defined on page 43 of the Condensed Financial Report, excludes Alcon, includes the businesses of Innovative Medicines and Sandoz, as well as the continuing corporate functions. 2Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 55 of the Condensed Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.
3 Please see detailed guidance assumptions on page 8 including the forecast assumption that we see a continuation of the return to normal global healthcare systems including prescription dynamics by mid 2021. In addition, we assume that no Gilenyaand noSandostatinLAR generics enter in 2021 in the US.